In a phase I clinical trial that tested the efficacy of CD19-CAR-T cells in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), it was found that 18 of 31 (58%) patients developed PHT (15). Here, CD19 is linked to diffuse large B-cell lymphoma.